Vaccines are an efficient and cost-effective therapy, proven to eradicate disease. The mucosal immune system is an integral part of host immunity, standing as the first line of defense against foreign invaders. Many pathogens are mucosally transmitted and initiate infection at mucosal surfaces, making these surfaces an excellent target for vaccine therapy.

LigoCyte’s focus on infectious disease and expertise in cellular immunology supports the development of mucosal vaccines. By targeting the mucosal immune system, our vaccines produce highly specific and targeted mucosal immune responses, providing superior protection over traditional vaccines. LigoCyte is developing the next generation of vaccines by combining the benefits of pain-free administration and protection at the sites most critical to infection.